Table 3. Association between CHRNA7 SNPs and LOAD by APOE ε4 status.
| Haplotype block | SNP/Haplotype (frequency among controls) | 0 copies |
1 or 2 copies |
Pinteraction | |||
|---|---|---|---|---|---|---|---|
| Case/Control | AOR | Case/Control | AOR (95% CI) | ||||
| 1 | SNP1 | All | 76/145 | 1.00 | 178/290 | 1.48 (0.94–2.32) | 0.23 |
| APOE ε4 (−) | 44/121 | 1.00 | 110/247 | 1.25 (0.73–2.13) | |||
| APOE ε4 (+) | 31/24 | 1.00 | 68/41 | 2.10 (0.89–4.94) | |||
| 1 | SNP2 | All | 182/348 | 1.00 | 68/84 | 1.53 (0.93–2.52) | 0.69 |
| APOE ε4 (−) | 111/294 | 1.00 | 40/71 | 1.52 (0.84–2.75) | |||
| APOE ε4 (+) | 70/52 | 1.00 | 28/13 | 1.68 (0.63–4.42) | |||
| 2 | SNP3 | All | 95/179 | 1.00 | 157/255 | 1.16 (0.76–1.79) | 0.62 |
| APOE ε4 (−) | 59/155 | 1.00 | 94/212 | 1.26 (0.76–2.09) | |||
| APOE ε4 (+) | 35/23 | 1.00 | 63/42 | 0.84 (0.35–2.02) | |||
| 3 | SNP4 | All | 77/139 | 1.00 | 176/293 | 1.50 (0.73–1.82) | 0.59 |
| APOE ε4 (−) | 48/125 | 1.00 | 105/241 | 1.22 (0.72–2.09) | |||
| APOE ε4 (+) | 28/14 | 1.00 | 71/50 | 0.84 (0.32–2.21) | |||
| 3 | SNP5 | All | 115/225 | 1.00 | 134/205 | 1.34 (0.88–2.04) | 0.15 |
| APOE ε4 (−) | 64/189 | 1.00 | 51/35 | 1.59 (0.97–2.61) | |||
| APOE ε4 (+) | 87/175 | 1.00 | 46/29 | 0.79 (0.35–1.81) | |||
| 3 | SNP6 | All | 109/181 | 1.00 | 143/253 | 0.79 (0.51–1.21) | 0.82 |
| APOE ε4 (−) | 75/161 | 1.00 | 79/207 | 0.79 (0.48–1.29) | |||
| APOE ε4 (+) | 34/20 | 1.00 | 63/44 | 0.65 (0.26–1.62) | |||
| 3 | SNP7 | All | 88/160 | 1.00 | 165/274 | 1.10 (0.72–1.71) | 0.23 |
| APOE ε4 (−) | 48/135 | 1.00 | 105/232 | 1.30 (0.77–2.20) | |||
| APOE ε4 (+) | 40/24 | 1.00 | 59/41 | 0.73 (0.32–1.66) | |||
| 4 | SNP8 | All | 219/352 | 1.00 | 32/78 | 0.50 (0.28–0.92) | 0.03 |
| APOE ε4 (−) | 135/298 | 1.00 | 16/66 | 0.29(0.13–0.64)* | |||
| APOE ε4 (+) | 83/52 | 1.00 | 16/12 | 1.32 (0.45–3.87) | |||
| 4 | SNP9 | All | 143/260 | 1.00 | 110/174 | 1.07 (0.70–1.64) | 0.10 |
| APOE ε4 (−) | 93/221 | 1.00 | 60/146 | 0.87 (0.53–1.44) | |||
| APOE ε4 (+) | 50/39 | 1.00 | 49/26 | 1.79 (0.78–4.07) | |||
| 4 | Hap1: AC | All | 14/33 | 1.00 | 240/402 | 1.37 (0.59–3.23) | 0.61 |
| (76%) | APOE ε4 (−) | 7/27 | 1.00 | 147/341 | 1.57 (0.56–4.41) | ||
| APOE ε4 (+) | 7/6 | 1.00 | 92/59 | 0.99 (0.19–5.04) | |||
| 4 | Hap2: AT | All | 171/319 | 1.00 | 83/116 | 1.34 (0.84–2.12) | 0.66 |
| (15%) | APOE ε4 (−) | 109/271 | 1.00 | 45/97 | 1.28 (0.74–2.21) | ||
| APOE ε4 (+) | 62/47 | 1.00 | 37/18 | 1.52 (0.62–3.73) | |||
| 4 | Hap3: GT | All | 222/357 | 1.00 | 32/78 | 0.49 (0.27–0.90) | 0.03 |
| (9%) | APOE ε4 (−) | 138/302 | 1.00 | 16/66 | 0.28 (0.13–0.63)* | ||
| APOE ε4 (+) | 83/53 | 1.00 | 16/12 | 1.30 (0.44–3.83) | |||
All models were adjusted for age, sex, APOE ε4, and education year and conditional on 5-year age strata. Numbers in bold indicate significant findings (P < 0.05). *The association remained significant after correction for multiple tests by false discovery rate (FDR). The effects of CHRNA7 haplotypes in block1 and block3 on LOAD risk are shown in Supplementary Table S1 because the results were non-significant after correction for multiple tests. Block2 included only one htSNP and was excluded from the haplotype analysis. Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; APOE, apolipoprotein E; Hap, haplotype.